Merck & Co. (NYSE:MRK) announced a quarterly dividend on Tuesday, May 27th, StockRatingsNetwork.com reports. Investors of record on Monday, June 16th will be paid a dividend of 0.44 per share on Tuesday, July 8th. This represents a $1.76 annualized dividend and a dividend yield of 3.01%. The ex-dividend date is Thursday, June 12th. Merck & Co., Inc. (NYSE:MRK) shares moved down -1.71% in last trading session and was closed at $57.53, while trading in range of $57.47 – $58.52. Merck & Co., Inc. (NYSE:MRK) year to date (YTD) performance is 16.72%.
Pfizer (NYSE:PFE) declared a quarterly dividend on Thursday, June 26th, Analyst Ratings Net reports. Investors of record on Friday, August 1st will be given a dividend of 0.26 per share on Wednesday, September 3rd. This represents a $1.04 dividend on an annualized basis and a yield of 3.51%. Pfizer Inc. (NYSE:PFE) net profit margin is 81.20% and weekly performance is -0.37%. On last trading day company shares ended up $29.67. Analysts mean target price for the company is $34.40. Pfizer Inc. (NYSE:PFE) distance from 50-day simple moving average (SMA50) is -0.26%.
Gilead Sciences, Inc. (NASDAQ:GILD)announced that the company has submitted a New Drug Application (NDA) to Japan’s Pharmaceutical and Medical Devices Agency (PMDA) for approval of sofosbuvir, a once-daily nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. The data in the NDA support the use of sofosbuvir with ribavirin (RBV) for 12 weeks in patients with genotype 2 HCV infection. If approved, sofosbuvir would form the basis of the first all-oral, interferon-free treatment regimen for genotype 2 patients in Japan. Gilead Sciences, Inc. (NASDAQ:GILD) shares advanced 0.92% in last trading session and ended the day on $82.94. GILD Gross Margin is 77.80% and its return on assets is 19.10%. Gilead Sciences, Inc. (NASDAQ:GILD) quarterly performance is 16.15%.
On June 17, 2014, Galena Biopharma Inc (NASDAQ:GALE)announced the completion of enrollment in the Company’s Phase 2a clinical trial for GALE-301, or Folate Binding Protein (FBP) peptide immunotherapy. GALE-301 is administered to HLA-A2 positive patients in combination with granulocyte macrophage-colony stimulating factor (GM-CSF) as an adjuvant treatment to prevent recurrences in high-risk, ovarian and endometrial cancer patients rendered disease-free after completing standard of care therapy. Galena Biopharma Inc (NASDAQ:GALE) ended the last trading day at $3.02. Company weekly volatility is calculated as 6.06% and price to cash ratio as 6.80. Gilead Sciences, Inc. (NASDAQ:GILD)showed a negative weekly performance of -0.33%.
On JUNE 1, 2014, ASTELLAS PHARMA INC (OTCMKTS:ALPMY), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo:4503) and Medivation, Inc. announced the online publication in the New England Journal of Medicine of the results from the Phase 3 PREVAIL trial, an international, randomized, double-blind, placebo-controlled clinical study of enzalutamide. The study evaluated the benefit and safety of enzalutamide in men with metastatic prostate cancer, who had few or no symptoms, that had progressed on luteinizing hormone-releasing hormone (LHRH) therapy or after bilateral orchiectomy. The paper, “Enzalutamide in Men with Metastatic Prostate Cancer Before Chemotherapy,” appears in the June 1 online issue and the companies anticipate publication in a future print issue of the Journal. ASTELLAS PHARMA INC (OTCMKTS:ALPMY) shares moved down -0.77% in last trading session and was closed at $12.96, while trading in range of $12.88 – $12.97.
Leave a Reply